Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell-cycle, phase-specific cell killing by carmustine in sensitive and resistant cells.

P A Linfoot1, M H Barcellos-Hoff, T P Brent

  • 1Department of Neurological Surgery, University of California, San Francisco 94143-0520.

NCI Monographs : a Publication of the National Cancer Institute
|January 1, 1988
PubMed
Summary

Carmustine (BCNU) cell kill varies by cell cycle phase. Guanine O6-alkyltransferase activity, a DNA repair protein, influences BCNU

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Oncogene·2016
Same author

ICRP Publication 131: Stem cell biology with respect to carcinogenesis aspects of radiological protection.

Annals of the ICRP·2016
Same author

ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection.

Annals of the ICRP·2015
Same author

TGF-β signaling links E-cadherin loss to suppression of nucleotide excision repair.

Oncogene·2015
Same author

In Vitro Cytotoxic Effects of Dibromodulcitol in 9L Rat Brain Tumor Cells.

Pharmaceutical research·2013
Same author

Polyamine-DNA Interactions: Possible Site of New Cancer Chemotherapeutic Intervention.

Pharmaceutical research·2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Carmustine (BCNU) is a chemotherapy drug used in cancer treatment.
  • Cell cycle phase influences drug sensitivity and efficacy.
  • Guanine O6-alkyltransferase (MGMT) is a DNA repair enzyme implicated in resistance to alkylating agents.

Purpose of the Study:

  • To investigate the cell-cycle phase-specific effects of carmustine (BCNU).
  • To determine the role of guanine O6-alkyltransferase activity in mediating BCNU-induced cell kill across different cell cycle phases.

Main Methods:

  • Four cell lines with varying BCNU sensitivities were utilized.
  • Cells were treated with BCNU, and synchronized subpopulations were isolated using centrifugal elutriation.
  • Cell survival was assayed, and guanine O6-alkyltransferase activity was measured.

Related Experiment Videos

Main Results:

  • One cell line (BTRC-19) with high alkyltransferase activity showed a relatively flat cell-cycle age-response curve to BCNU.
  • Cell lines lacking detectable alkyltransferase activity exhibited increased sensitivity in G1 and G2/M phases compared to S phase.
  • A correlation between alkyltransferase activity and resistance to BCNU was observed.

Conclusions:

  • Guanine O6-alkyltransferase activity may be a dominant factor in determining BCNU's cell-cycle phase specificity.
  • The presence of this repair enzyme can override other cell-cycle-dependent mechanisms of drug sensitivity.
  • Understanding MGMT's role is crucial for optimizing BCNU-based cancer therapies.